{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:02:49Z","timestamp":1790467369082,"version":"4.1.0"},"reference-count":23,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,5]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>We compared daunorubicin\/cytarabine plus fractionated gemtuzumab ozogamicin (DAGO2) with CPX-351 (CPX; 1:2 randomization) in 439 patients with acute myeloid leukemia (AML) aged \u226560 years (median age, 68 years) without known adverse-risk cytogenetics. Median follow-up was 35 months. Patients not in measurable residual disease (MRD)-negative remission after course 1 could enter a second randomization between standard and intensified chemotherapy. Post\u2013course 1, the overall response rate (complete remission [CR] + CR with incomplete hematological recovery) was greater after DAGO2 (60% vs 47.5%; odds ratio [OR], 0.61; P = .016). Following course 2, the overall response was not significantly different (85% for DAGO2 vs 78% for CPX; P = .095). More patients attained CR with MRD negativity after course 1 in the DAGO2 arm (47% vs 29% for CPX; OR, 0.46; P = .004). We observed better 3-year event-free survival (34% vs 27%; hazard ratio [HR], 0.73; P = .012) and overall survival (52% vs 35%; HR, 0.62; P = .001) with DAGO2. CPX did not provide a survival benefit in patients with myelodysplasia (MDS)\u2013related mutations and was associated with poorer survival in patients with NPM1 (HR, 2.83) and FLT3 mutations (HR, 2.14). Overall, 37% of patients underwent transplantation in first remission, with no difference in transplantation frequency or survival after transplant between randomization groups. Among patients entering the course 2 randomization (n = 107), survival was equivalent between standard and intensified CPX doses (P = .565). In conclusion, in this population of older patients with AML without known adverse-risk cytogenetics, DAGO2 resulted in superior survival compared with CPX. CPX did not benefit patients with MDS-related mutations over DAGO2. This trial was registered at www.ClinicalTrials.gov as #NCT02272478.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025031006","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T20:43:43Z","timestamp":1763153023000},"page":"1048-1057","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non\u2013adverse-risk AML: the NCRI AML18 trial"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6405-4441","authenticated-orcid":false,"given":"Steven","family":"Knapper","sequence":"first","affiliation":[{"name":"1Division of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4877-9354","authenticated-orcid":false,"given":"Laura W.","family":"Dillon","sequence":"additional","affiliation":[{"name":"2Fralin Biomedical Research Institute, Virginia Tech Fralin Biomedical Research Institute, Cancer Research Center, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malavika","family":"Babu","sequence":"additional","affiliation":[{"name":"3Centre for Trials Research, Cardiff University, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8283-6762","authenticated-orcid":false,"given":"Abin","family":"Thomas","sequence":"additional","affiliation":[{"name":"3Centre for Trials Research, Cardiff University, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Thomas","sequence":"additional","affiliation":[{"name":"3Centre for Trials Research, Cardiff University, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6189-8067","authenticated-orcid":false,"given":"Christopher S.","family":"Hourigan","sequence":"additional","affiliation":[{"name":"2Fralin Biomedical Research Institute, Virginia Tech Fralin Biomedical Research Institute, Cancer Research Center, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Andrew","sequence":"additional","affiliation":[{"name":"4Laboratory of Myeloid Malignancies, National Heart, Lung, and Blood Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Dillon","sequence":"additional","affiliation":[{"name":"5Department of Medical and Molecular Genetics, Kings College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Gilkes","sequence":"additional","affiliation":[{"name":"1Division of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Marquez Almuina","sequence":"additional","affiliation":[{"name":"3Centre for Trials Research, Cardiff University, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"King","sequence":"additional","affiliation":[{"name":"3Centre for Trials Research, Cardiff University, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"McCarthy","sequence":"additional","affiliation":[{"name":"6Department of Clinical Immunology Service, School of Infection, Inflammation and Immunology, University of Birmingham College of Medicine and Health, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1608-712X","authenticated-orcid":false,"given":"Reem","family":"Bahr","sequence":"additional","affiliation":[{"name":"2Fralin Biomedical Research Institute, Virginia Tech Fralin Biomedical Research Institute, Cancer Research Center, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha W.","family":"Al-Ali","sequence":"additional","affiliation":[{"name":"2Fralin Biomedical Research Institute, Virginia Tech Fralin Biomedical Research Institute, Cancer Research Center, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2750-4757","authenticated-orcid":false,"given":"Louisa","family":"Stone","sequence":"additional","affiliation":[{"name":"7Clinical Haematology, Auckland City Hospital, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4341-4361","authenticated-orcid":false,"given":"Tom","family":"Coats","sequence":"additional","affiliation":[{"name":"8Department of Clinical Haematology, Royal Devon and Exeter NHS Foundation Trust, Exeter, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Byrne","sequence":"additional","affiliation":[{"name":"9Department of Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Green","sequence":"additional","affiliation":[{"name":"10Department of Clinical Haematology, Castle Hill Hospital, Hull, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrik Malthe","family":"Overgaard","sequence":"additional","affiliation":[{"name":"11Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob S.","family":"Sellar","sequence":"additional","affiliation":[{"name":"12University College London Cancer Institute, University College London Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2540-8673","authenticated-orcid":false,"given":"Mike","family":"Dennis","sequence":"additional","affiliation":[{"name":"13Department of Haematology, The Christie NHS Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8561-1705","authenticated-orcid":false,"given":"Priyanka","family":"Mehta","sequence":"additional","affiliation":[{"name":"14Department of Haematology, The University of Bristol and Weston NHS Trust, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hills","sequence":"additional","affiliation":[{"name":"15Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1869-180X","authenticated-orcid":false,"given":"Sylvie D.","family":"Freeman","sequence":"additional","affiliation":[{"name":"6Department of Clinical Immunology Service, School of Infection, Inflammation and Immunology, University of Birmingham College of Medicine and Health, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel H.","family":"Russell","sequence":"additional","affiliation":[{"name":"16Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"32","key":"2026030511215434100_bib1","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2012.42.2964","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia","volume":"30","author":"Burnett","year":"2012","journal-title":"J Clin Oncol"},{"issue":"20","key":"2026030511215434100_bib2","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1182\/blood.2023020630","article-title":"Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial","volume":"142","author":"Freeman","year":"2023","journal-title":"Blood"},{"issue":"3","key":"2026030511215434100_bib3","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1365-2141.2009.07604.x","article-title":"The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial","volume":"145","author":"Burnett","year":"2009","journal-title":"Br J Haematol"},{"key":"2026030511215434100_bib4","first-page":"00259","article-title":"Treatment intensification with either fludarabine, AraC, G-CSF and idarubicin, or cladribine plus daunorubicin and AraC on the basis of residual disease status in older patients with AML: results from the NCRI AML18 trial","volume":"24","author":"Russell","year":"2024","journal-title":"J Clin Oncol"},{"issue":"26","key":"2026030511215434100_bib5","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J Clin Oncol"},{"issue":"32","key":"2026030511215434100_bib6","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1200\/JCO.2013.49.1753","article-title":"Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia","volume":"31","author":"Freeman","year":"2013","journal-title":"J Clin Oncol"},{"issue":"16","key":"2026030511215434100_bib7","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1182\/bloodadvances.2023010276","article-title":"A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial","volume":"7","author":"Othman","year":"2023","journal-title":"Blood Adv"},{"issue":"S3","key":"2026030511215434100_bib8","doi-asserted-by":"crossref","first-page":"e0819670","DOI":"10.1097\/01.HS9.0000967436.08196.70","article-title":"A randomised assessment of the sequential addition of the kinase inhibitor quizartinib to intensive chemotherapy in older acute myeloid leukaemia (AML) patients: results from the NCRI AML18 trial [abstract]","volume":"7","author":"Knapper","year":"2023","journal-title":"HemaSphere"},{"issue":"3","key":"2026030511215434100_bib9","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2026030511215434100_bib10","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"issue":"26","key":"2026030511215434100_bib11","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on measurable residual disease (MRD) in acute myeloid leukemia (AML): a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"8","key":"2026030511215434100_bib12","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1200\/JCO.21.01548","article-title":"Response rate, event-free survival, and overall survival in newly diagnosed acute myeloid leukemia: US Food and Drug Administration trial-level and patient-level analyses","volume":"40","author":"Norsworthy","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"2026030511215434100_bib13","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"issue":"24","key":"2026030511215434100_bib14","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026030511215434100_bib15","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"issue":"12","key":"2026030511215434100_bib16","doi-asserted-by":"crossref","first-page":"E462","DOI":"10.1002\/ajh.26730","article-title":"Secondary-type mutations do not impact prognosis in acute myelogenous leukemia AML with mutated NPM1","volume":"97","author":"Wright","year":"2022","journal-title":"Am J Hematol"},{"issue":"1","key":"2026030511215434100_bib17","doi-asserted-by":"crossref","first-page":"e70060","DOI":"10.1002\/hem3.70060","article-title":"Impact of myelodysplasia-related and additional gene mutations in intensively treated patients with NPM1-mutated AML","volume":"9","author":"Cocciardi","year":"2025","journal-title":"Hemasphere"},{"issue":"7","key":"2026030511215434100_bib18","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/blood.2024024310","article-title":"Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML","volume":"144","author":"Othman","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2026030511215434100_bib19","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1158\/2643-3230.BCD-23-0144","article-title":"Criteria for diagnosis and molecular monitoring of NPM1-mutated AML","volume":"5","author":"Falini","year":"2024","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"2026030511215434100_bib20","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/bjh.19622","article-title":"CREST-UK: real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UK","volume":"205","author":"Mehta","year":"2024","journal-title":"Br J Haematol"},{"issue":"4","key":"2026030511215434100_bib21","doi-asserted-by":"crossref","first-page":"100123","DOI":"10.1016\/j.bneo.2025.100123","article-title":"V-FAST: A phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AML","volume":"2","author":"Pullarkat","year":"2025","journal-title":"Blood Neoplasia"},{"issue":"4","key":"2026030511215434100_bib22","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1080\/10428194.2024.2438809","article-title":"CPX-351 plus gemtuzumab ozogamicin for relapsed\/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial","volume":"66","author":"Oliai","year":"2024","journal-title":"Leuk Lymphoma"},{"issue":"suppl 1","key":"2026030511215434100_bib23","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1182\/blood-2024-205666","article-title":"A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin (GO) to CPX-351 with GO-a report from the Children\u2019s Oncology Group [abstract]","volume":"144","author":"Pollard","year":"2024","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/10\/1048\/2506852\/blood_bld-2025-031006-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/10\/1048\/2506852\/blood_bld-2025-031006-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T16:22:11Z","timestamp":1772727731000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/10\/1048\/548218\/CPX-351-vs-daunorubicin-cytarabine-and-gemtuzumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,3,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025031006","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,5]]},"published":{"date-parts":[[2026,3,5]]}}}